131 related articles for article (PubMed ID: 22658535)
1. Polymer conjugates of acridine-type anticancer drugs with pH-controlled activation.
Sedláček O; Hrubý M; Studenovský M; Větvička D; Svoboda J; Kaňková D; Kovář J; Ulbrich K
Bioorg Med Chem; 2012 Jul; 20(13):4056-63. PubMed ID: 22658535
[TBL] [Abstract][Full Text] [Related]
2. Polymeric anticancer drugs with pH-controlled activation.
Ulbrich K; Subr V
Adv Drug Deliv Rev; 2004 Apr; 56(7):1023-50. PubMed ID: 15066758
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?
Baguley BC; Wakelin LP; Jacintho JD; Kovacic P
Curr Med Chem; 2003 Dec; 10(24):2643-9. PubMed ID: 14529454
[TBL] [Abstract][Full Text] [Related]
4. Fine tuning of the pH-dependent drug release rate from polyHPMA-ellipticinium conjugates.
Sedláček O; Studenovský M; Větvička D; Ulbrich K; Hrubý M
Bioorg Med Chem; 2013 Sep; 21(18):5669-72. PubMed ID: 23941688
[TBL] [Abstract][Full Text] [Related]
5. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.
Etrych T; Sírová M; Starovoytova L; Ríhová B; Ulbrich K
Mol Pharm; 2010 Aug; 7(4):1015-26. PubMed ID: 20518512
[TBL] [Abstract][Full Text] [Related]
6. Expedient synthesis and anticancer evaluation of dual-action 9-anilinoacridine methyl triazene chimeras.
Walunj D; Egarmina K; Tuchinsky H; Shpilberg O; Hershkovitz-Rokah O; Grynszpan F; Gellerman G
Chem Biol Drug Des; 2021 Feb; 97(2):237-252. PubMed ID: 32772433
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, DNA-cleaving properties and cytotoxicity of intercalating chelidamic acid derivatives.
Searcey M; McClean S; Madden B; McGown AT; Wakelin LP
Anticancer Drug Des; 1998 Dec; 13(8):837-55. PubMed ID: 10335263
[TBL] [Abstract][Full Text] [Related]
8. Demonstrating the importance of polymer-conjugate conformation in solution on its therapeutic output: Diethylstilbestrol (DES)-polyacetals as prostate cancer treatment.
Giménez V; James C; Armiñán A; Schweins R; Paul A; Vicent MJ
J Control Release; 2012 Apr; 159(2):290-301. PubMed ID: 22230343
[TBL] [Abstract][Full Text] [Related]
9. A molecular modeling study of B-DNA-intercalation complexes with amsacrine and related 9-anilino-acridines.
Fischer G; Pindur U
Pharmazie; 1999 Feb; 54(2):83-93. PubMed ID: 10084153
[TBL] [Abstract][Full Text] [Related]
10. Ellipticine-aimed polymer-conjugated auger electron emitter: multistage organelle targeting approach.
Sedlacek O; Hruby M; Studenovsky M; Kucka J; Vetvicka D; Kovar L; Rihova B; Ulbrich K
Bioconjug Chem; 2011 Jun; 22(6):1194-201. PubMed ID: 21513348
[TBL] [Abstract][Full Text] [Related]
11. In vitro anticancer activity and evaluation of DNA duplex binding affinity of phenyl-substituted indoloquinolines.
Riechert-Krause F; Eick A; Grünert R; Bednarski PJ; Weisz K
Bioorg Med Chem Lett; 2011 Apr; 21(8):2380-3. PubMed ID: 21414783
[TBL] [Abstract][Full Text] [Related]
12. Development of efficient acid cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell.
Calderón M; Welker P; Licha K; Fichtner I; Graeser R; Haag R; Kratz F
J Control Release; 2011 May; 151(3):295-301. PubMed ID: 21256902
[TBL] [Abstract][Full Text] [Related]
13. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
[TBL] [Abstract][Full Text] [Related]
14. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
15. Polyacetal-stilbene conjugates - The first examples of polymer therapeutics for the inhibition of HIF-1 in the treatment of solid tumours.
England RM; Masiá E; Giménez V; Lucas R; Vicent MJ
J Control Release; 2012 Dec; 164(3):314-22. PubMed ID: 22940127
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antitumor activity of novel amsacrine analogs: the critical role of the acridine moiety in determining their biological activity.
Chilin A; Marzaro G; Marzano C; Dalla Via L; Ferlin MG; Pastorini G; Guiotto A
Bioorg Med Chem; 2009 Jan; 17(2):523-9. PubMed ID: 19101158
[TBL] [Abstract][Full Text] [Related]
17. Polymeric anticancer drugs with pH-controlled activation.
Ulbrich K; Etrych T; Chytil P; Pechar M; Jelinkova M; Rihova B
Int J Pharm; 2004 Jun; 277(1-2):63-72. PubMed ID: 15158969
[TBL] [Abstract][Full Text] [Related]
18. A novel water soluble ligand bridged cobalt(II) coordination polymer of 2-oxo-1,2-dihydroquinoline-3-carbaldehyde (isonicotinic) hydrazone: evaluation of the DNA binding, protein interaction, radical scavenging and anticancer activity.
Raja DS; Bhuvanesh NS; Natarajan K
Dalton Trans; 2012 Apr; 41(15):4365-77. PubMed ID: 22354161
[TBL] [Abstract][Full Text] [Related]
19. 'Minimal' DNA-intercalating agents as anti-tumour drugs: 2-styrylquinoline analogues of amsacrine.
Denny WA; Atwell GJ; Baguley BC
Anticancer Drug Des; 1987 Dec; 2(3):263-70. PubMed ID: 3449090
[TBL] [Abstract][Full Text] [Related]
20. Novel water-soluble and pH-responsive anticancer drug nanocarriers: doxorubicin-PAMAM dendrimer conjugates attached to superparamagnetic iron oxide nanoparticles (IONPs).
Chang Y; Meng X; Zhao Y; Li K; Zhao B; Zhu M; Li Y; Chen X; Wang J
J Colloid Interface Sci; 2011 Nov; 363(1):403-9. PubMed ID: 21821262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
